This review synthesizes subgroup analyses and real-world data to guide the selection of non-vitamin K antagonist oral anticoagulants for stroke prevention in high-risk atrial fibrillation patients.
What is the optimal Non-vitamin K Antagonist Oral Anticoagulant strategy for stroke prevention in high-risk atrial fibrillation patients?
This expert review provides perspectives on tailoring NOAC therapy for stroke prevention in complex AF patient populations in Vietnam.
Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on primary and secondary stroke prevention. Part 2 explores the management of AF in special, high-risk and clinically common patient populations, including those with renal impairment, diabetes, the elderly, and those with coronary artery disease. Furthermore, Part 2 addresses the challenges posed by patients with AF who have a bioprosthetic valve, a group situated in a grey area of consideration. Managing AF in these patient groups presents unique clinical challenges that require careful consideration. Physicians are tasked with addressing specific clinical questions to identify the optimal anticoagulation strategy for each individual. To inform these decisions, subgroup analyses from pivotal studies are presented alongside real-world data derived from clinical practice. By synthesising available information and considering the nuanced clinical context, the aim is to provide informed perspectives that align with current medical knowledge and contribute to the enhancement of patient care in these challenging scenarios.
Ton et al. (Fri,) conducted a review in Atrial Fibrillation. Non-vitamin K Antagonist Oral Anticoagulant was evaluated. This review synthesizes subgroup analyses and real-world data to guide the selection of non-vitamin K antagonist oral anticoagulants for stroke prevention in high-risk atrial fibrillation patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: